β³ Fetching live dividend data...
Home βΊ Calculator βΊ RVNC Dividend Calculator 2026
Revance Therapeutics, Inc. Β· NASDAQ
Price: $3.65 Β· Annual div: None Β· Frequency: β Β· Payout ratio: N/A Β· Ex-div: β
RVNC is not a dividend-focused stock
RVNC pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Revance Therapeutics, Inc. (RVNC) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Revance Therapeutics, Inc. is a biotechnology company specializing in the research, manufacturing, and marketing of neuromodulators for diverse aesthetic and therapeutic uses across both domestic and international markets. The company's leading product candidate, DaxibotulinumtoxinA for injection, has concluded Phase III clinical evaluations for treating glabellar (frown) lines and cervical dystonia. This same drug is currently in Phase II clinical trials for addressing upper facial lines, moderate to severe dynamic forehead lines, and moderate to severe lateral canthal lines, following the successful completion of its Phase II trials for adult upper limb spasticity and plantar fasciitis. Beyond this, Revance is conducting preclinical studies for DaxibotulinumtoxinA as a potential migraine treatment and is developing a topical version for various indications. The company is also developing OnabotulinumtoxinA, intended as a biosimilar to BOTOX. A collaborative and licensing partnership with Viatris Inc. facilitates the development, manufacturing, and commercialization of onabotulinumtoxinA. Initially established in 1999 as Essentia Biosystems, Inc., the company officially rebranded as Revance Therapeutics, Inc. in April 2005 and maintains its corporate headquarters in Nashville, Tennessee.
No. Revance Therapeutics, Inc. (RVNC) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. RVNC has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data Β· open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open RVNC position with:
Real after-tax yield depends on where you live and how you hold RVNC.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| π©πͺ DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| π«π· FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
RVNC pays quarterly β 4 times per year. Ex-div: β.
How RVNC compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for RVNC sourced from FMP /financial-growth endpoint β real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| U-Tender | 2025-02-04 | 30,106 | $3.65 | $109.9K | ||
| D-Return | 2025-02-06 | 15,000 | β | β | ||
| A-Award | 2025-02-06 | 84,686 | β | β | ||
| U-Tender | 2025-02-04 | 996,935 | $3.65 | $3.64M | ||
| U-Tender | 2025-02-04 | 110,913 | $3.65 | $404.8K | ||
| D-Return | 2025-02-06 | 84,686 | β | β | ||
| U-Tender | 2025-02-04 | 97,999 | $3.65 | $357.7K | ||
| A-Award | 2025-02-06 | 20,883 | β | β | ||
| D-Return | 2025-02-06 | 20,883 | β | β | ||
| U-Tender | 2025-02-04 | 47,815 | $3.65 | $174.5K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Compare RVNC with peers: RVNC vs BCYP Β· RVNC vs CKPT Β· RVNC vs CLYM
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the RVNC dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
Revance Therapeutics, Inc. (RVNC) is currently trading at $3.65, 52% below its 52-week high. It does not currently pay a regular dividend.
Revance Therapeutics, Inc. (RVNC) is a healthcare stock trading at $3.65. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only β not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
β±οΈ Takes 30 seconds Β· No signup Β· Free forever